TP53 codon 72 gene polymorphism paradox in associated with various carcinoma incidences, invasiveness and chemotherapy responses

International Journal of Biomedical Science

Volumn 4, Issue 4, 2008, Pages 248-254

  Lin, Hung Yu ^a,b   Huang, Chun Hsiung ^c   Wu, Wen Jen ^c   Chang, Li Ching ^a   Lung, For Wey ^c,d,e,f  

^a I SHOU UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^f Calo Psychiatric Center   (Taiwan)

Author keywords

Apoptosis; Codon 72; TP53

Indexed keywords

ARGININE; CYTOCHROME C; PROLINE; PROTEIN P53;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENESIS; CARCINOMA; CELL CYCLE REGULATION; CODON; CYTOSOL; DATA ANALYSIS; DNA DAMAGE; DNA POLYMORPHISM; DRUG RESPONSE; ENVIRONMENTAL FACTOR; EXON; GENE MUTATION; HEREDITY; HUMAN; HYPOTHESIS; MEDLINE; MITOCHONDRION; PROGNOSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN VARIANT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 77749298444     PISSN: 15509702     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Yamaguchi K, Sugano K, Fukayama N, et al. Polymerase chain reaction-based approaches for detection of allelic loss in the p53 tumor suppressor gene in colon neoplasms. Am. J. Gastroenterol. 1997; 92:307.
2. Ko LJ, Prives C. p53: Puzzle and paradigm. Genes. Dev. 1996; 10:1054.
3. Rand A, Glenn KS, Alvares CP, et al. p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles. Cancer Lett. 1996; 98:183.
4. Chang FH, Tzeng DS, Lee TM, et al. Mutations in the p53 tumor suppressor gene in colorectal cancer in Taiwan. Kaohsiung J. Med. Sci. 2003; 19:151.
5. Lin HY, Huang CH, Wu WJ, et al. Mutation of the p53 tumor suppressor gene in transitional cell carcinoma of the urinary tract in Taiwan. Kaohsiung J. Med. Sci. 2005; 21:54.
6. Vidaurreta M, Maestro ML, Sanz-Casla MT, et al. Colorectal carcinoma prognosis can be predicted by alterations in gene p53 exons 5 and 8. Int. J. Colorectal Dis. 2008; 23:581.
7. Cui W, Kong X, Cao HL, et al. Mutations of p53 Gene in 41 Cases of Human Brain Gliomas. Ai Zheng 2008; 27:8.
8. Matlashewski GJ, Tuck S, Pim D, et al. Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell Biol. 1987; 7:961.
9. Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 2006; 25:3489.
10. Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 2000; 25:47.
11. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393:229.
12. Thomas M, Kalita A, Labrecque S, et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell Biol. 1999; 19:1092.
13. Dumont P, Leu JI, Della Pietra AC, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 2003; 33:357.
14. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int. J. Cancer 2004; 108:196.
15. Bonafe M, Salvioli S, Barbi C, et al. The different apoptotic potential of the p53 codon 72 alleles increases with age and modulates in vivo ischaemia-induced cell death. Cell Death Differ. 2004; 11:962.
16. Marchenko ND, Zaika A, Moll UM. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J. Biol. Chem. 2000; 275:16202.
17. Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004; 23:3328.
18. Cortezzi SS, Provazzi PJ, Sobrinho JS, et al. Analysis of human papillomavirus prevalence and TP53 polymorphism in head and neck squamous cell carcinomas. Cancer Genet. Cytogenet. 2004; 150:44.
19. Yang W, Zhang Y, Tian X, Ning T, Ke Y. p53 Codon 72 polymorphism and the risk of esophageal squamous cell carcinoma. Mol. Carcinog. 2008; 47:100.
20. Sousa H, Santos AM, Pinto D, Medeiros R. Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? Int. J. Mol. Med. 2007; 20:731.
21. Papadakis EN, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol. Cell. Biol. Res. Commun. 2000; 3:389.
22. Ohayon T, Gershoni-Baruch R, Papa MZ, et al. The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br. J. Cancer 2005; 92:1144.
23. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 2002; 179:175.
24. Brant O, Hoffmann M, Kanappilly A, Gorogh T, Gottschlich S. P53 codon 72 polymorphism in squamous cell carcinoma of the head and neck region. Anticancer Res. 2007; 27:3301.
25. Wang YC, Chen CY, Chen SK, Chang YY, Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin. Cancer Res. 1999; 5:129.
26. Jin X, Wu X, Roth JA, et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 1995; 16:2205.
27. Hu Y, McDermott MP, Ahrendt SA. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res. 2005; 11:2502.
28. Kuroda Y, Tsukino H, Nakao H, Imai H, Katoh T. p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett. 2003; 189:77.
29. Bergamaschi G, merante S, Orlandi E, et al. TP53 codon 72 polymorphism in patients with chronic myeloid leukemia. Haematologica 2004; 89:868.
30. Zhu ZZ, Wang AZ, Jia HR, et al. Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn. J. Clin. Oncol. 2007; 37:385.
31. Ezzikouri S, El Feydi AE, Chafik A, et al. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res. 2007; 37:748.
32. Hadhri-Guiga B, Toumi N, Khabir A, et al. Proline homozygosity in codon 72 of TP53 is a factor of susceptibility to nasopharyngeal carcinoma in Tunisia. Cancer Genet. Cytogenet. 2007; 178:89.
33. Vikhanskaya F, Siddique MM, Kei Lee M, Broggini M, Sabapathy K. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. Clin. Cancer. Res. 2005; 11:4348.
34. Yuan P, Miao XP, Zhang XM, et al. Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms. Zhonghua Zhong Liu Za Zhi. 2006; 28(2):107.
35. Han JY, Lee GK, Jang DH, Lee SY, Lee JS. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008; 113:799.
36. Toyama T, Zhang Z, Nishio M, et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res. 2007; 9(3):R34.
37. Galic V, Willner J, Wollan M, et al. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer. 2007; 46(3):239.
38. Chen WC, Tsai FJ, Wu JY, et al. Distributions of p53 codon 72 polymorphism in bladder cancer - proline form is prominent in invasive tumor. Urol. Res. 2000; 28:293.
39. Lung FW, Lee TM, Shu BC, Chang FH. p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J. Cancer Res. Clin. Oncol. 2004; 130:728.
40. Wu WJ, Kakehi Y, Habuchi T, et al. Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn. J. Cnacer Res. 1995; 86:730.
41. Idbaih A, Boisselier B, Marie Y, et al. TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. Cancer Genet. Cytogenet. 2007; 177:103.
42. Phang BH, Linn YC, Li H, Sabapathy K. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur. J. Cancer. 2008; 44(5):760.
43. Siddique MM, Balram C, Fiszer-Maliszewska L, et al. Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol. Biomarkers. Prev. 2005; 14:2245.